Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Equity to Asset ratio can vary greatly across different industries, as they have different capital structure. A company with smaller Equity to Asset ratio (more leveraged) may have higher ROE % because of the leverage.
For banks, the required minimum Equity to Asset ratio by regulation is 5%. Some stronger banks may have Equity to Asset Ratio of more than 10%.
BioPlus Acquisition Equity-to-Asset Related Terms
BioPlus Acquisition Equity-to-Asset Historical Data
* Premium members only.
The historical data trend for BioPlus Acquisition's Equity-to-Asset can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
BIOSW vs SBII, GWII, AHPA: Equity-to-Asset Comparison
For the Shell Companies subindustry, BioPlus Acquisition's Equity-to-Asset, along with its competitors' market caps and Equity-to-Asset data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
BioPlus Acquisition Equity-to-Asset vs Diversified Financial Services Industry
For the Diversified Financial Services industry and Financial Services sector, BioPlus Acquisition's Equity-to-Asset distribution charts can be found below:
* The bar in red indicates where BioPlus Acquisition's Equity-to-Asset falls into.
Equity to Asset ratio measures the ratios of the portion of the asset owned by shareholders out of the total asset. It indicates the leverage of the company, and the amount of debt the company uses in its operation.
Equity to Asset ratio is calculated by dividing total stockholders equity by total asset.
BioPlus Acquisition's Equity to Asset Ratio for the fiscal year that ended in Dec. 2022 is calculated as
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
BioPlus Acquisition (BIOSW) has a Equity-to-Asset of 0.88 as of Jun. 2023. Equity-to-asset ratio equals total company equity divided by total assets. It measures financial leverage. View historical data on BioPlus Acquisition and its competitors. This is near median its historical median of 0.94. Over the past decade, BioPlus Acquisition's Equity-to-Asset has ranged from 0.04 to 0.94.
Is BioPlus Acquisition's Equity-to-Asset too high?
BioPlus Acquisition's current Equity-to-Asset of 0.88 is near median its 10-year median of 0.94. Over the past 10 years, this metric has ranged from a low of 0.04 to a high of 0.94. The Diversified Financial Services industry median Equity-to-Asset is 0.91. BioPlus Acquisition's value of 0.88 is 3.3% below this industry median. Overall, BioPlus Acquisition has a GF Score™ of 21/100, reflecting its overall financial health beyond just this single metric.
How does BioPlus Acquisition's Equity-to-Asset compare to SBII and GWII?
BioPlus Acquisition's Equity-to-Asset of 0.88 can be compared against companies in the Diversified Financial Services industry. The industry median Equity-to-Asset is 0.91. BioPlus Acquisition's value of 0.88 is 3.3% below this benchmark. Historically, BioPlus Acquisition's own Equity-to-Asset has ranged from 0.04 to 0.94 over the past decade. While the company's 10-year median is 0.94 vs. the industry median of 0.91, BioPlus Acquisition has consistently been below the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Equity-to-Asset for a Diversified Financial Services company?
The median Equity-to-Asset among Diversified Financial Services companies is 0.91, based on 528 companies in the industry. Companies in the top quartile (top 25%) have a Equity-to-Asset significantly above this median, while those in the bottom quartile fall well below. However, Equity-to-Asset should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. BioPlus Acquisition's current Equity-to-Asset of 0.88 is 3.3% below the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Equity-to-Asset mean?
A high Equity-to-Asset can signal that a stock is expensive relative to its fundamentals. Equity-to-asset ratio equals total company equity divided by total assets. It measures financial leverage. View historical data on BioPlus Acquisition and its competitors. For the Diversified Financial Services industry, the median Equity-to-Asset is 0.91 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. BioPlus Acquisition's current Equity-to-Asset is 0.88, which is near median its own 10-year median of 0.94. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is BioPlus Acquisition stock overvalued right now?
BioPlus Acquisition (BIOSW) has a current Equity-to-Asset of 0.88. The current Equity-to-Asset is 0.88, which is near median its 10-year median of 0.94 and 3.3% below the Diversified Financial Services industry median of 0.91. BioPlus Acquisition's overall GF Score™ is 21/100. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Equity-to-Asset calculated?
Equity-to-Asset is calculated from a company's financial statements. For BioPlus Acquisition (BIOSW), the current Equity-to-Asset is 0.88 as of Jun. 2023. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
BIOSW has been successfully added to your 
